Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ABBV-47D11 and ABBV-2B04 in Adults With COVID-19
NCT04644120Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2020
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, randomised, double-blind trial of ABBV-47D11 and ABBV-2B04 in coronavirus disease 2019 (COVID-19) (12 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants With Study-Drug Related Grade 3 or Higher Adverse Events and Number of Participants With Study-Drug Related Grade 3 or Higher Infusion-Related Reactions. Started Dec 2020; status: completed.
02
Drugs
ABBV-47D11ABBV-2B04
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04644120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04644120.